A Double‐Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects
2019 ◽
Vol 13
(2)
◽
pp. 337-344
◽